Navigation Links
New UK study shows potential for targeting aggressive breast cancers
Date:2/11/2014

LEXINGTON, Ky. (Feb. 10, 2014) A new study led by University of Kentucky Markey Cancer Center researcher Peter Zhou shows that targeting Twist, a nuclear protein that is an accelerant of the epithelial-mesenchymal transition (EMT) program in human cells, may provide an effective approach for treating triple-negative breast cancer.

Triple-negative breast cancer has an activated EMT program, which is a process that provides cells with the increased plasticity (or flexibility) to adapt to stressed environments during embryonic development, wound healing, tissue fibrosis and metastasis. EMT provides tumor cells with stem cell-like characteristics, making them resistant to therapeutics and increasing their chances for early metastasis.

Triple-negative breast cancer in particular is associated with an aggressive clinical history, development of recurrence, distant metastasis and shorter patient survival, especially in younger women. It lacks effective targeted therapies and often displays early metastatic spread to brain and lung, sites known to be associated with an estimated 5-year survival of less than 20 percent.

Published in Cancer Cell, the study found that the nuclear protein Twist acts similarly to a virus protein. Using protein purification, Zhou's team identified that Twist interacted with a key nuclear transcription regulator BRD4. When many DNA viruses (such as papillomaviruses) enter into human "host" cells during infection, they hijack host cell machinery to replicate and synthesis their viral DNA and proteins. BRD4 is the virus's favored molecule and is often seized by DNA papillomaviruses for gene transcription during replication and growth.

Twist uses a similar strategy to recruit BRD4 to the genomic regions that are regulated by Twist. Many of these genomic regions contain oncogenes, such as those of survival proteins, growth factors and molecules that enhance cell migration and invasion. By recruiting BRD4 to these genomic regions, Twist accelerates cell growth and invasion by "waking up" the expression of these oncogenes.

Additionally, the study showed that two BRD4 inhibitors, JQ1 and MS417, can specifically disrupt the interaction of Twist with BRD4, resulting in the suppression of invasion, stem cell-like characters and tumorigenicity of triple-negative breast cancer cells.

"This finding has significant clinical ramification, because drugs that can target the Twist-BRD4 interaction provide a new hope for treating life-threatening triple-negative breast cancer," said Zhou, associate professor of molecular and cellular biochemistry at UK.

Jian Shi, a post-doctoral fellow at UK Markey Cancer Center, was the first author of this study, and other collaborators include UK Markey Cancer Center director Dr. Mark Evers and researchers Chi Wang and Haining Zhu. Previously, Zhou and his team have studied the role of the Snail complex also known as the cellular "brake" in contrast to Twist's accelerant in the EMT program.


'/>"/>

Contact: Allison Perry
allison.perry@uky.edu
859-323-2399
University of Kentucky
Source:Eurekalert

Related medicine news :

1. UNC study reveals potential route to bladder cancer diagnostics, treatments
2. Dartmouth study provides first global evidence that foreign aid boosts public opinion
3. Study: Resilience in parents of children undergoing stem cell transplant
4. Grant supports Cedars-Sinai study of possible links between air pollution and brain cancer
5. Study provides surprising new clue to the roots of hunger
6. Study identifies protein to repair damaged brain tissue in MS
7. Ice ages arctic tundra lush with wildflowers for woolly mammoths, study finds
8. Director of Womens Guild Lung Institute awarded grant to study treatment for lung disease
9. Columbia study finds hospitals dont follow infection prevention rules
10. Penn study reveals genetics impact risk of early menopause among some female smokers
11. New study finds feeling in control can help you live longer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, eyewear, ... the rarified air of pop and film stardom.(1) Not to be left out is ... smile. Grins now run the gamut from being encrusted with jewels and precious metals ...
(Date:4/24/2017)... ... ... The John P. McGovern Museum of Health and Medical Science is now partnered with ... share results with their physicians. Members and guests can sign up for its free ... Dr. David Eagleman, formerly at Baylor College of Medicine and now at Stanford University, ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new ... is not known to have significant interactions with antiretroviral therapy (ART). Among ... levels and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... shows that over the last decade, student well-being has seriously declined. "When disenfranchised ... of formal education, join the Islamic State to turn the historic multi-ethnic and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... -- Viverae ® , a leader in workplace wellness ... ® Watson Campaign Automation, implementing behavioral messaging within ... personalized experience. Through digital engagement, the platform prompts members ... time. The enhanced experience drives engagement by focusing on ... are in their journey to health. ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc. and SOINN ... in 2016, in which Socionext extracts and delivers ... companies achieved initial results in reading ultrasound images ... Brain SOINN. The results will be introduced at ... 19-21, at booths 4505 & 4507. ...
Breaking Medicine Technology: